{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T02:43:02Z","timestamp":1789612982682,"version":"build-2803163510"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Dupilumab is licensed for the treatment of moderate-to-severe atopic dermatitis (AD) in patients aged \u2265 6\u2005months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>The aim of this study was to examine real-world outcomes and safety of dupilumab in British children with moderate-to-severe AD attending a tertiary referral paediatric centre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Skin and quality of life scores, adverse events and discontinuation rates were assessed. Patients aged \u2264 18\u2005years with moderate-to-severe AD were included if they had skin scores recorded at baseline and at least one follow-up visit. Efficacy and safety were assessed using descriptive statistics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In this retrospective observational survey, 72 children\/teenagers, with a median age of 14\u2005years (range 7\u201318) were included. Oral systemic immunosuppressants had failed to control AD in 88% of children recruited. All patients commenced on dupilumab had pretreatment eczema skin scores consistent with moderate-to-severe disease, with a median Eczema Area and Severity Index (EASI) score of 25 [interquartile range (IQR) 20\u201331]. EASI scores decreased by a median of 94% (IQR 82\u2013100) and remained consistently low over 10\u201352\u2005months of the study, with a median EASI score at final follow-up of 2 (IQR 0\u20136). Of the 72 children, 8 (11%) were able to discontinue dupilumab as they were in remission. Nineteen (26%) experienced adverse events, most commonly conjunctivitis (12 patients; 17%). Eight (11%) discontinued dupilumab (six with ongoing inflammatory skin flares, one with severe allergic conjunctivitis, one with intercurrent Wilson disease).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Dupilumab was highly effective in treating most children with moderate-to-severe AD with good safety outcomes in the real world. However, 10% of children may need alternative therapy because of drug ineffectiveness or side-effects.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ced\/llae013","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T21:33:25Z","timestamp":1704404005000},"page":"578-583","source":"Crossref","is-referenced-by-count":16,"title":["Real-world outcomes of children treated with dupilumab for moderate-to-severe atopic dermatitis: a single-centre retrospective observational UK study"],"prefix":"10.1093","volume":"49","author":[{"given":"Mozhgan","family":"Hosseini-Ashrafi","sequence":"first","affiliation":[{"name":"Faculty of Biology, Medicine and Health, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim H","family":"Clayton","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology, Royal Manchester Children\u2019s Hospital , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Herring","sequence":"additional","affiliation":[{"name":"Department of Paediatric Allergy & Immunology, Royal Manchester Children\u2019s Hospital , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichola","family":"Herety","sequence":"additional","affiliation":[{"name":"Department of Paediatric Dermatology, Royal Manchester Children\u2019s Hospital , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter\u00a0D","family":"Arkwright","sequence":"additional","affiliation":[{"name":"Department of Paediatric Allergy & Immunology, Royal Manchester Children\u2019s Hospital , Manchester , UK"},{"name":"The Lydia Becker Institute of Immunology and Inflammation, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,1,8]]},"reference":[{"key":"2024052116304084400_llae013-B1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.anai.2020.12.020","article-title":"Atopic dermatitis in the pediatric population: a cross-sectional, international epidemiologic study","volume":"126","author":"Silverberg","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"2024052116304084400_llae013-B2","doi-asserted-by":"crossref","first-page":"adv00160","DOI":"10.2340\/00015555-3510","article-title":"Prevalence and incidence of atopic dermatitis: a systematic review","volume":"100","author":"Bylund","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2024052116304084400_llae013-B3","doi-asserted-by":"crossref","first-page":"adv00161","DOI":"10.2340\/00015555-3511","article-title":"Counting the burden: atopic dermatitis and health-related quality of life","volume":"100","author":"Ali","year":"2020","journal-title":"Acta Derm Venereol"},{"key":"2024052116304084400_llae013-B4","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1111\/j.1742-1241.2006.01047.x","article-title":"Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema","volume":"60","author":"Lewis-Jones","year":"2006","journal-title":"Int J Clin Pract"},{"key":"2024052116304084400_llae013-B5","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjd.15928","article-title":"Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement","volume":"178","author":"Drucker","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024052116304084400_llae013-B6","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1111\/jdv.18410","volume":"36","author":"de Graaf","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024052116304084400_llae013-B7","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11\u2005years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024052116304084400_llae013-B8","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S0140-6736(22)01539-2","article-title":"Dupilumab in children aged 6\u2005months to younger than 6\u2005years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"400","author":"Paller","year":"2022","journal-title":"Lancet"},{"key":"2024052116304084400_llae013-B9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1001\/jamadermatol.2019.3336","article-title":"Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial","volume":"156","author":"Simpson","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024052116304084400_llae013-B10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40257-022-00683-2","article-title":"Long-term efficacy and safety of dupilumab in adolescents with moderate-to-severe atopic dermatitis: results through week 52 from a phase III open-label extension trial (LIBERTY AD PED-OLE)","volume":"23","author":"Blauvelt","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"2024052116304084400_llae013-B11","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-020-00577-1","article-title":"Conjunctivitis in dupilumab clinical trials for adolescents with atopic dermatitis or asthma","volume":"22","author":"Bansal","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"2024052116304084400_llae013-B12","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/jdv.18141","article-title":"Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: a multicentre Italian real-world experience","volume":"36","author":"Stingeni","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2024052116304084400_llae013-B13","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jaip.2022.06.014","article-title":"Dupilumab improves clinical scores in children and adolescents with moderate to severe atopic dermatitis: a real-world, single-center study","volume":"10","author":"Pagan","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024052116304084400_llae013-B14","doi-asserted-by":"crossref","first-page":"e15588","DOI":"10.1111\/dth.15588","article-title":"A 24-weeks real-world experience of dupilumab in adolescents with moderate-to-severe atopic dermatitis","volume":"35","author":"Napolitano","year":"2022","journal-title":"Dermatol Ther"},{"key":"2024052116304084400_llae013-B15","article-title":"Efficacy of dupilumab in children 6\u2005months to 11\u2005years old with atopic dermatitis: a retrospective real-world study in China","author":"Yang","year":"2023","journal-title":"Dermatitis"},{"key":"2024052116304084400_llae013-B16","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/jcm12031175","article-title":"Efficacy and treatment satisfaction of different systemic therapies in children and adolescents with moderate-to-severe atopic dermatitis: a real-world study","volume":"12","author":"Kiefer","year":"2023","journal-title":"J Clin Med"},{"key":"2024052116304084400_llae013-B17","doi-asserted-by":"crossref","first-page":"2246602","DOI":"10.1080\/09546634.2023.2246602","article-title":"A 52-week multicenter retrospective real-world study on effectiveness and safety of dupilumab in children with atopic dermatitis aged from 6 to 11\u2005years","volume":"34","author":"Patruno","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"2024052116304084400_llae013-B18","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/pde.15418","article-title":"Multicenter Canadian case series of pediatric patients less than 12\u2005years of age with moderate-to-severe atopic dermatitis treated with dupilumab","volume":"41","author":"Martinez-Cabriales","year":"2024","journal-title":"Pediatr Dermatol"},{"key":"2024052116304084400_llae013-B19","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/jdv.19409","article-title":"Dupilumab therapy in children aged 2\u201312\u2005years with uncontrolled moderate-to-severe atopic dermatitis: a Chinese real-world study","volume":"38","author":"Zhou","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae013\/56826868\/llae013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/6\/578\/57800594\/llae013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/49\/6\/578\/57800594\/llae013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T16:30:59Z","timestamp":1716309059000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/49\/6\/578\/7512767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,8]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,1,8]]},"published-print":{"date-parts":[[2024,5,21]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae013","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,1,8]]}}}